Compare SA & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SA | ICUI |
|---|---|---|
| Founded | 1979 | 1984 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medical/Dental Instruments |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.9B |
| IPO Year | 2004 | 1995 |
| Metric | SA | ICUI |
|---|---|---|
| Price | $33.43 | $132.23 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | $65.00 | ★ $182.25 |
| AVG Volume (30 Days) | ★ 840.0K | 262.1K |
| Earning Date | 01-01-0001 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.62 |
| EPS | N/A | ★ 0.03 |
| Revenue | N/A | ★ $2,231,262,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.10 |
| P/E Ratio | ★ N/A | $4,574.00 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.40 | $107.02 |
| 52 Week High | $40.06 | $160.29 |
| Indicator | SA | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 46.97 | 31.28 |
| Support Level | $28.46 | $125.04 |
| Resistance Level | N/A | $136.39 |
| Average True Range (ATR) | 1.86 | 6.40 |
| MACD | -0.39 | -1.98 |
| Stochastic Oscillator | 29.53 | 9.83 |
Seabridge Gold Inc is a development stage company involved in the exploration, and development of gold properties sited in North America. The company's principal projects include the Kerr-Sulphurets-Mitchell property located in British Columbia, the Courageous Lake property located in the Northwest Territories, and Iksut Property located in northwestern British Columbia, and the 3 Aces Project in southeast Yukon. The company has various other mineral resource projects throughout North America.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.